Population Pharmacokinetics of Therapeutic Monoclonal Antibodies, Clinical Pharmacokinetics, vol.27, issue.7, pp.633-59, 2010. ,
DOI : 10.2165/11535960-000000000-00000
Population pharmacokinetic (popPK) model of pembrolizumab (pembo; MK-3475) in patients (pts) treated inKEYNOTE-001 and KEYNOTE-002, J Clin Oncol, vol.33, 2015. ,
Phase I study of pembrolizumab (MK-3475 ,
Pembrolizumab for the Treatment of Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.372, issue.21, pp.2018-2046, 2015. ,
DOI : 10.1056/NEJMoa1501824
Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development, Clinical Pharmacology & Therapeutics, vol.24, issue.2, pp.167-74, 2009. ,
DOI : 10.1093/jnci/92.3.205
Exploratory Modeling and Simulation to Support Development of Motesanib in Asian Patients With Non???Small Cell Lung Cancer Based on MONET1 Study Results, Clinical Pharmacology & Therapeutics, vol.118, issue.4, pp.446-51, 2014. ,
DOI : 10.1038/clpt.2012.78
A Review of Mixed-Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis, CPT Pharmacometrics Syst. Pharmacol., vol.59, issue.5, p.113, 2014. ,
DOI : 10.1016/j.jtbi.2012.12.013